Pharmaceutical Companies in the Philippines

FDA Philippines issues the Certificate of Product Registration. Statutory review targets exist, but industry commentary still describes real clocks of one to several years for new molecules, which is why launch calendars are built around the agency rather than around a sales meeting. Once registered, an imported innovator almost always appoints Zuellig Pharma — and sometimes its affiliate Metro Drug — to warehouse, invoice and deliver; those two houses have long been estimated to carry the large majority of organised wholesale. Unilab and a handful of other local manufacturers run their own sales forces into doctors and their own or contracted logistics into Mercury Drug, Watsons and the generics chains. PhilHealth’s role is growing but still incomplete: the Universal Health Care Act automatically enrolls citizens, yet many medicines sit outside case-rate packages or are only partly covered, so the patient (or a private HMO) pays the pharmacy. DOH procures for retained hospitals and for public-health programmes, and local government units buy for their own facilities, producing a fragmented public channel rather than a single national tender. The Generics Act and the cheaper RiteMed / Pharex / TGP offer have shifted unit share toward branded generics, but originator value remains high in private hospitals and in specialty clinics. Interphil, in Laguna, is the plant foreign companies name when they want local manufacture without building a factory. For any new brand the practical questions are FDA timing, Zuellig or Metro Drug appointment, Mercury Drug ranging, and whether a PhilHealth package will ever touch the molecule.

The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in the Philippines:

Matching listicle and country brief, sibling directories in the Philippines, and the same directory for neighbouring markets.